Loading...
619. Acute myeloid leukemias: disease burden and measurable residual disease in prognosis and treatment FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond npm1 PCR-MRD: analysis of the UK NCRI AML17 and AML19 trials
Tedjaseputra, A. Potter, N. Jovanovic, J. Ivey, A. Runglall, M. Villiers, W. Aucken, P. Lim, M. Arumugam, T. Grimwade, O.
Tedjaseputra, A.
Potter, N.
Jovanovic, J.
Ivey, A.
Runglall, M.
Villiers, W.
Aucken, P.
Lim, M.
Arumugam, T.
Grimwade, O.
Abstract
Authors
Tedjaseputra, A.
Potter, N.
Jovanovic, J.
Ivey, A.
Runglall, M.
Villiers, W.
Aucken, P.
Lim, M.
Arumugam, T.
Grimwade, O.
Gilkes, A.
Canham, J.
Johnson, S.
Thomas, I.
Ommen, H.
Overgaard, U.
Spearing, R.
Dennis, M.
O'Nions, J.
King, A.
Cahalin, P.
Mehta, P.
Taussig, D.
Solomo, E.
Burnett, A.
Freeman, S.
Knapper, S.
Wei, A.
Othman, J.
Russell, N.
Dillon, R.
Potter, N.
Jovanovic, J.
Ivey, A.
Runglall, M.
Villiers, W.
Aucken, P.
Lim, M.
Arumugam, T.
Grimwade, O.
Gilkes, A.
Canham, J.
Johnson, S.
Thomas, I.
Ommen, H.
Overgaard, U.
Spearing, R.
Dennis, M.
O'Nions, J.
King, A.
Cahalin, P.
Mehta, P.
Taussig, D.
Solomo, E.
Burnett, A.
Freeman, S.
Knapper, S.
Wei, A.
Othman, J.
Russell, N.
Dillon, R.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 175.54 KB
Keywords
Type
Article
Citation
Tedjaseputra A, Potter N, Jovanovic J, Ivey A, Runglall M, Villiers W, et al. 619. Acute myeloid leukemias: disease burden and measurable residual disease in prognosis and treatment FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond npm1 PCR-MRD: analysis of the UK NCRI AML17 and AML19 trials. Blood. 2025 NOV 3;146:345-6.